InterCure (IL:INCR)
TASE:INCR
Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪159.80M
Enterprise Value283.64M
Total Cash (Recent Filing)₪51.58M
Total Debt (Recent Filing)₪179.34M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding59,228,558
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Operating And Free Cash FlowInterCure generated positive operating (~16.8M) and free cash flow (~13.3M) in 2025, reversing prior outflows. Sustained positive FCF improves the firm's ability to fund operations, invest in cultivation/retail, and service debt without relying on equity raises, strengthening medium-term operational resilience.
Manageable Balance-sheet LeverageLeverage declined to a roughly 0.46 debt-to-equity ratio in 2025, improving from 0.53 the prior year. This moderate leverage provides financial flexibility to withstand volatility, supports continued investment in cultivation and retail, and lowers acute refinancing risk over the next several quarters.
Diversified Medical Cannabis Revenue Channels And RecoveryInterCure operates both wholesale supply and branded retail dispensaries and saw revenue rebound +11.1% in 2025. The dual-channel model supports stable demand capture, improves margin mix control through retail, and the 2025 recovery suggests end-market demand or better commercialization supporting medium-term revenue durability.
Bears Say
Persistent Net LossesDespite narrower losses in 2025, InterCure remained loss-making across 2023–2025 with a -13.2% net margin in 2025. Continued multi-year deficits erode retained equity, limit internal funding for growth initiatives, and require consistent profitability to secure long-term capital efficiency and avoid dilution or debt accumulation.
Gross Margin CompressionSharp gross margin compression versus prior years signals pressure on pricing, cost of cultivation, or product mix. Persistent margin erosion undermines the path to sustainable operating profit even if revenues recover, making long-term margin restoration essential for durable cash generation and return on invested capital.
Cash-flow Volatility And Negative ROEThe 2025 cash-flow improvement followed substantial outflows in 2023–2024, and ROE has been negative for three consecutive years. Such volatility and persistently negative ROE indicate the firm’s capital base isn’t generating returns, raising the risk that future losses could deplete equity or force dilutive financing.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪159.80M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 56 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 59,228,558 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.